HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry

Histopathology

Volumn 48, Issue 6, 2006, Pages 702-707

  Park, K ^a   Han, S ^a   Kim, H J ^a   Kim, J ^a   Shin, E ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Ductal carcinoma in situ; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Invasive ductal carcinoma; Metastasis; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 33646007353     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02403.x     Document Type: Article

References (25)

1. Stern DF Heffernan PA Weinberg RA p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity MolCellBiol 1986 6 1729 1740
2. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WJ Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 177 182
3. Paik S Hazan R Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer JClinOncol 1990 8 103 112
4. Toikkanen S Helin H Isola J Joensuu H Prognostic significance of HER-2 oncoprotein expression in breast cancer. A 30-yr follow-up JClinOncol 1992 10 1044 1048
5. Muss HB Thor AD Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer NEnglJMed 1994 330 1260 1266
6. Paik S Bryant J Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer JNatl Cancer Inst 1998 90 1361 1370
7. Bartkova J Barnes DM Millis RR Gullick WJ Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ HumPathol 1990 21 1164 1167
8. Julien JP Bijker N Fentiman IS et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Lancet 2000 355 528 533
9. Houghton J George WD Cuzick J Duggan C Fentiman IS Spittle M UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 2003 362 95 102
10. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer - experience from a large study with long-term follow-up Histopathology 1991 19 403 410
11. Silverstein MJ Poller DN Waisman JR et al. Prognostic classification of breast ductal-carcinoma-in-situ Lancet 1995 345 1154 1157
12. Park K Kim J Lim S Han S Lee JY Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray ModPathol 2003 16 937 943
13. Gusterson BA Machin LG Gullick WJ et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer IntJCancer 1988 42 842 845
14. Soomro S Shousha S Taylor P Shepard HM Feldmann M c-erbB-2 expression in different histological types of invasive breast carcinoma JClinPathol 1991 44 211 214
15. Sommerville JE Clarke LA Biggart JD c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma JClinPathol 1992 45 16 20
16. Allred DC Clark GM Molina R et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer HumPathol 1992 23 974 979
17. Iglehart JD Kerns BJ Huper G Marks JR Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phase of mammary cancer Breast Cancer ResTreat 1995 34 253 263
18. Morya T Silverberg SG Intraductal carcinoma (ductal carcinoma in situ) of the breast: a comparison of pure noninvasive tumors with those including different proportion of infiltrating carcinoma Cancer 1994 74 2972 2978
19. Muthuswamy SK Li D Lelievre S Bissell MJ Brugge JS ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini NatCellBiol 2001 3 785 792
20. van de Vijver MJ Peterse JL Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer NEnglJMed 1988 319 1239 1245
21. Lodato RF Maguire HCJ Greene MI Weiner DB LiVolsi VA Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast ModPathol 1990 3 449 454
22. Latta EK Tjan S Parkes RK O'Malley FP The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast ModPathol 2002 15 1318 1325
23. Thor AD Berry DA Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer JNatl Cancer Inst 1998 90 1346 1360
24. Simon R Nocito A Hubscher T et al. Pattern of her-2/neu amplification and overexpression in primary and metastatic breast cancer JNatl Cancer Inst 2001 93 1120 1121
25. Carlson J Nordgren H Sjostrom J et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review BrJCancer 2004 90 2344 2348